Roche Says Weight-Loss Shot Achieved Positive Results in Midstage Trial

Core Insights - A late-stage trial program of CT-388 is expected to start this quarter [1] Company and Industry Summary - The initiation of the late-stage trial program indicates a significant advancement in the development of CT-388, which may impact the company's position in the market [1] - The timing of the trial program suggests that the company is progressing towards potential commercialization of CT-388, which could lead to new revenue streams [1] - The late-stage trials are critical for assessing the efficacy and safety of CT-388, which will be essential for regulatory approval and market entry [1]